| Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology JA Ajani, TA D’Amico, DJ Bentrem, J Chao, D Cooke, C Corvera, P Das, ... Journal of the National Comprehensive Cancer Network 20 (2), 167-192, 2022 | 714 | 2022 |
| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ... Annals of Oncology 30 (7), 1096-1103, 2019 | 554 | 2019 |
| Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK … N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ... Cancer discovery 11 (8), 1913-1922, 2021 | 285 | 2021 |
| Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence SJ Klempner, D Fabrizio, S Bane, M Reinhart, T Peoples, SM Ali, ... The oncologist 25 (1), e147-e159, 2020 | 278 | 2020 |
| Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ... Gastroenterology 156 (8), 2242-2253. e4, 2019 | 266 | 2019 |
| Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ... Clinical Cancer Research 27 (20), 5586-5594, 2021 | 239 | 2021 |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ... Journal of gastrointestinal oncology 9 (4), 610, 2018 | 230 | 2018 |
| Targeted therapy in cancer AM Tsimberidou Cancer chemotherapy and pharmacology 76, 1113-1132, 2015 | 223 | 2015 |
| Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK … SHI Ou, M Azada, DJ Hsiang, JM Herman, TS Kain, C Siwak-Tapp, ... Journal of Thoracic Oncology 9 (4), 549-553, 2014 | 196 | 2014 |
| What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway SJ Klempner, AP Myers, LC Cantley Cancer discovery 3 (12), 1345-1354, 2013 | 160 | 2013 |
| Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C R Yaeger, J Weiss, MS Pelster, AI Spira, M Barve, SHI Ou, TA Leal, ... New England Journal of Medicine 388 (1), 44-54, 2023 | 141 | 2023 |
| Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In … SM Ali, T Hensing, AB Schrock, J Allen, E Sanford, K Gowen, A Kulkarni, ... The oncologist 21 (6), 762-770, 2016 | 139 | 2016 |
| Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability–high gastric cancer M Kwon, M An, SJ Klempner, H Lee, KM Kim, JK Sa, HJ Cho, JY Hong, ... Cancer discovery 11 (9), 2168-2185, 2021 | 134 | 2021 |
| Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma C Ang, SJ Klempner, SM Ali, R Madison, JS Ross, EA Severson, ... Oncotarget 10 (40), 4018, 2019 | 129 | 2019 |
| Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors AB Schrock, VW Zhu, WS Hsieh, R Madison, B Creelan, J Silberberg, ... Journal of Thoracic Oncology 13 (9), 1312-1323, 2018 | 125 | 2018 |
| Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping SHI Ou, L Young, AB Schrock, A Johnson, SJ Klempner, VW Zhu, ... Journal of Thoracic Oncology 12 (1), 137-140, 2017 | 122 | 2017 |
| Identification and characterization of RET fusions in advanced colorectal cancer AF Le Rolle, SJ Klempner, CR Garrett, T Seery, EM Sanford, ... Oncotarget 6 (30), 28929, 2015 | 122 | 2015 |
| Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer A Dehal, AN Graff-Baker, B Vuong, T Fischer, SJ Klempner, SC Chang, ... Journal of Gastrointestinal Surgery 22 (2), 242-249, 2018 | 110 | 2018 |
| Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences K Wang, A Johnson, SM Ali, SJ Klempner, T Bekaii-Saab, JL Vacirca, ... The oncologist 20 (10), 1132-1139, 2015 | 102 | 2015 |
| Targeted therapy for gastric cancer: molecular pathways and ongoing investigations W Yang, A Raufi, SJ Klempner Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 232-237, 2014 | 96 | 2014 |
Alexa SchrockVerified email at foundationmedicine.com
